Creating a successful commercial organization: Delivering against our promise to help people living with cancer

Throughout my career, I’ve sought opportunities to work with outstanding scientists, drug developers and commercialization colleagues to partner on innovations that can have a substantial impact on human health. Once you have been part of a team delivering transformative outcomes to patients, you don’t want to do anything else. Nothing scares me more than wasting a career on mediocrity. That innate drive to create solutions for difficult challenges, as well as a desire to make a significant impact on human outcomes, has fueled my commitment to people living with cancer. It’s the same fire that motivates so many of my colleagues at Mirati: Despite the challenge, we are relentlessly focused on creating better options to enable a life beyond cancer for patients and their families.

Despite the challenge, we are relentlessly focused on creating better options to enable a life beyond cancer for patients and their families.

Our pipeline, and now, our products, are proof of our commitment to patients. The KRASG12C mutation is notoriously challenging, despite being the most commonly occurring KRAS mutation in non-small cell lung cancer (NSCLC).1 Understanding the challenge and need for innovation, our scientists set out to create and deliver better treatments for patients. Now, there is a new option.

We are proud of our products’ potential as a new treatment option, and we’re especially excited to bring these life-changing options to people living with cancer. It’s not enough to create a new innovation; to ensure patient impact, they, their caretakers and their doctors must be educated about their treatment options, and they must have access. Mirati is working to ensure people living with cancer will have unrestricted and affordable patient access through competitive pricing, support services such as Mirati & Me and partnerships across the nation with community oncologists and distributors. We are also working to educate both patients and oncologists, as well as increasing testing and patient identification efforts, to ensure people living with cancer are matched with treatments that best meet their needs.

After more than 20 years of building and leading commercialization functions and capabilities at various organizations, I’m proud of the relentless dedication of Mirati’s team to improving the lives of people with cancer and the high level of scientific innovation we’ve maintained. We’re excited to continue driving value for the cancer community, and we have great potential to change people’s lives through our therapies.

I’m proud of the relentless dedication of Mirati’s team to improving the lives of people with cancer and the high level of scientific innovation we’ve maintained.

At Mirati’s core is a willingness to learn, explore and adapt. By staying open to diverse perspectives and mindsets, we are able to continuously improve our work and make new discoveries. Mirati’s discovery programs are prime examples of this—our scientific curiosity will propel our future success as we continue developing and discovering new therapies in the targeted oncology space.

As we look to the future, Mirati has the opportunity to establish new standards of care for people living with cancer affected by the KRASG12C mutation globally. Through our products and pipeline, our potential for patient impact is significant. This opportunity means we needed to create, and now, sustain a commercial vehicle to deliver on our promise to patients and commitment to shareholders.

With the wealth of opportunity in our pipeline and our team driven, patient first culture, we have the opportunity to drive commercialization success, and deliver life-changing medicines to people living with cancer.

  1. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):e120858. doi:10.1172/jci.insight.120858

How innovation has the potential to change patients’ lives

Today, the Mirati Drug Discovery, Research and Early Development teams are exceptional and productive groups of scientists working across all stages of the project initiation, discovery and early drug development process. This growth has been one of the biggest and most vital, changes for Mirati, as it has allowed our innovation to continue. We are now able to capitalize on our successes, grow our capabilities and advance our portfolio of life-changing therapies.

As a scientist, I love the thrill of making new discoveries and solving the different challenges that arise. I’m thrilled about our discovery and development projects, which pursue greater innovations and explore breakthroughs that have the potential to target cancer. Our discovery projects begin by identifying tumor-driving cellular processes in cancer patients and continues when we bring together scientists from the Drug Discovery and Research teams to identify new molecules with the potential to precisely target those processes.

I love the thrill of making new discoveries and solving the different challenges that arise.

The discovery of a potential new medicine can be lengthy and difficult, and we must sometimes create hundreds or even thousands of unique compounds before we find one that has the potential to be an investigational new drug candidate. The Drug Discovery group’s collaboration with other Mirati teams–including Research, Drug Metabolism and Early Development–helps us determine which compounds to pursue and advance toward clinical development. Once a therapy enters clinical trials, we are hopeful about the value our drug candidates may have for patients and excited to hear about the progress of those clinical studies.

When I first started at Mirati, we had the desire to make a difference in patients’ lives, which fueled us to expand and advance our portfolio of life-changing therapies. Our sustained commitment to innovation, growing talent across various teams and dedication to improving patients’ lives provides us the opportunity to continue developing a broad portfolio of targeted oncology projects.

During our rapid growth, one thing has remained constant at Mirati: our common commitment to discover and develop new treatments with the potential to transform the lives of patients living with cancer. We have been–and will always be–a patient-centric organization, and our focus on improving patients’ lives is what drives us forward.

Building a global medical team from the ground up

Kelly is passionate about helping patients with cancer and her work at Mirati leading the Medical Affairs team. Below, she answers questions that offer a holistic view of her role as the Head of Medical Affairs at Mirati and details why she decided to work for the company.

Q. Did you always want to be in STEM, or in biotech more specifically, and was there something that drew you to it?

A. I always knew I wanted a career in science and healthcare. I transitioned from training in academia to pharma and biotech because I enjoy working more directly on science that is making a difference for treating a disease. My day-to-day now involves leading a team to communicate the science to different audiences, such as patients or physicians, to help address questions and generate data that continues to inform and support clinical practice and access in the real world. It is crucial that I understand all the data and science extremely well, so I am able to apply my background and have the chance to see the impact on the day-to-day with the patients and physicians we work with.

Q. Considering the breadth of the biotech industry, why did you choose to work at Mirati?

A. Firstly, Mirati is an oncology-focused company, where the lead indications of both main assets at the time were for lung cancer. I have a strong background in and passion for lung cancer, and I was excited to bring that to the company. Secondly – the science. I am a scientist by training, and I need to truly believe in the drugs I work on. I find both sitravatinib and adagrasib interesting for their own reasons and believe they will fill an unmet need in lung cancer. Thirdly – the role itself. The opportunity to build out a team and new function for the company from scratch doesn’t happen all that often. I was very intrigued to have this unique experience.

Q. What were you most excited about when you first joined Mirati?

A. Beyond the science and pipeline, I was most excited about the people and culture. Everyone I met had the same passion for working hard and working together to do good things for patients and the investigators we work with. People were down to earth and fun, but also very competent and hard working. Mirati has a good challenge with many opportunities for a relatively small biotech and I love the fearless nature of people and the teams are determined to make anything happen – including what may seem impossible.

Q. Can you explain your role at Mirati in relation to the KRAS programs?

A. I lead a team that touches several different facets of the KRAS program. We help support enrollment in the trials, including working to remove any potential barriers to enrollment. We help communicate the data. There are many workstreams around this. Communication can include one-on-one in the doctor’s office, engagement with payers, meeting with patients or patient advocacy groups, presentations at medical conferences or data dissemination in peer reviewed journals. Our team also established a call center for inquiries and will be supporting continued medical education. Additionally, our team had a big role at American Society of Clinical Oncology (ASCO) 2022 where we engaged with >250 physicians and patients/groups and had 2 oral presentations with a simultaneous NEJM manuscript. Finally, we also help to generate data against any gaps that exist such as understanding the activity of the drug in patient population excluded from the clinical trials, providing evidence to support how the adverse events can be managed and demonstrating the value of our drugs. We have done all the above for our current lead asset; from driving the enrollment of the various KRYSTAL trials and we also now have ISRs, an early access program, and other studies-whether be clinical, economic, or real-world evidence-to generate data to inform practice and support access to our assets.

Q. When you were hired, you were essentially a team of one and then slowly you grew your team. How did you build a high-performing Global Medical function for the company from the ground up?

A. It has been crazy how fast two years has gone by and the amount of growth and change that has occurred in that time. I came here to build something from scratch, so it is incredibly rewarding to see how the team came together. I am biased but I think we have a best-in-industry team.

As we built out the team, we were deliberate in hiring for key behaviors and values – team players who will work hard and together to figure things out do good things for the patients, physicians, team and company. We were deliberate in building a diverse team hiring PhDs, PharmDs, Nurses, and MDs that had different experiences across pharma, biotech, targeted therapies and immuno-oncology. While building out my team, it helped tremendously that Mirati has incredible science and late-stage assets, but also the pipeline we are looking to build. It is exciting. The incredible people and culture already at Mirati helped us recruit an amazing team that is a great fit with the company culture.

Q. As someone with leadership experience yourself, how would you define leadership? And in your experience, what makes a strong leader?

A. For myself, I am learning to be authentic and embrace my style. First and foremost, a leader should be kind and care about the people. Good leaders are results driven, competent and confident but also has a learning mindset because nobody is perfect or knows everything. I try to encourage a fearless culture where everyone has a voice and opportunity to express ideas. Strong leaders hire good people, empower them and get out of their way but are accessible and offer support when needed. I am transparent – teams and people do their best when they know as much information and context as possible – and I’m direct – setting clear expectations on outcomes and not afraid to advocate for my team or speak the truth in tough circumstances when tensions or barriers arise. Finally, a good leader is someone who can stay positive with a calm demeanor and upbeat attitude, especially through challenging situations.

Q. What would you say is the best part of being in a leadership position?

A. The best part about being in a leadership position is being able to support and empower people, especially those who don’t believe in themselves as much as I do and who are still growing and developing. I have had great leaders throughout my career, and the ones I’ve gravitated toward and remember are those who not only strive for results, but who genuinely care about and believe in people. I enjoy giving others new opportunities, coaching and feedback to be able to continue to grow professionally and achieve new heights in their careers.

Stepping outside your professional comfort zone

Below, Vanessa shares her perspective for those considering a career in STEM. She offers a thoughtful perspective on how to step out of your comfort zone to take advantage of opportunities to advance your career. She discusses universal obstacles many individuals face when considering new, challenging roles that could offer significant career growth, including fear and familial obligations.

I work at Mirati as the vice president of clinical development operations, where I help support the clinical development organization with initiatives related to continuous improvement and operational efficiencies.

I have worked in the biotech industry for 26 years, but I began in a different space than where I am today. I have a pre-med background, but I started my career at a clinical research organization. Even though I had no idea where it would lead me, I kept an open mind. It can be intimidating to consider a STEM career, but there are so many avenues to find the area within this industry that is right for you.

It can be intimidating to consider a STEM career, but there are so many avenues to find the area within this industry that is right for you.

I encourage young professionals to understand there are a variety of opportunities regardless of background or education. For individuals with no experience in a specific industry, it is important to get your foot in the door in your interest area because there is so much growth that can happen within a role. My advice is to accept that a role may elicit feelings of hesitancy but use it to your maximum advantage. Step outside your comfort zone and try something new because that is when you thrive.

I encourage young professionals to understand there are a variety of opportunities regardless of background or education.

I love my current role at Mirati, but I was not always fulfilled with my career. I stayed well within my comfort zone for many years in a previous role, but I didn’t have a lot of growth opportunities because I could only go so far with the qualifications that I had. Although I was content in my role and would have stayed, I received the chance to join a new company that would provide exciting opportunities. The new role had the potential to expand beyond my comfort zone and taking the job would require a leap of faith. This new position ended up being a great learning experience. I realized that making changes and taking chances can open up many opportunities for professional and personal growth.

I would strongly advise others to not let fear keep you immobilized in a role with no growth potential. Give yourself that chance. Once you have succeeded in a certain role, keep moving forward and grow. Throughout my career, I’ve had several conversations with my colleagues who have been doing one avenue of work for a significant period of time and are afraid when presented with a different opportunity.

It is not always the easiest decision to change, especially when you have obligations, like family. When considering a new opportunity, you might be more inclined to stay if your current situation is comfortable and stable. I also have seen other factors – such as concerns of handling additional responsibility or having to travel frequently – affect whether to take a new opportunity, especially for working mothers. I went through that myself and have had that same conversation with some of my colleagues.

It has been encouraging to see my female colleagues go through similar journeys, where they started in a certain role just to get experience then found specific interests and inspirations that led them to executive roles in various companies.

Ultimately, you can never know with complete certainty if a new opportunity is right for you until you try. Once you acknowledge the opportunity and choose to commit to the unknown, your growth potential increases dramatically. And if it doesn’t work, at least you’ve tried. Allow yourself to learn what you capable of, you may surprise yourself!

Ultimately, you can never know with complete certainty if a new opportunity is right for you until you try.

My advice to someone who is interested in taking a leap of faith professionally, but does not know whether the timing is right, is to not focus on evaluating the timing of the move. It is easy to get wrapped up in thinking about the various reasons why the timing of a move may be bad, but don’t restrict yourself. I think we use timing as an excuse, and we make excuses because of fear. However, we move forward and grow by overcoming our fears.

We should all be able to have an adequate life-work balance that allows us to grow as an individual in all our roles, as a partner, a mom, and a colleague. Fortunately, we continue to see improvements in the workplace to accommodate individuals to ensure they can bring their best selves to work and strive for the career that they want. I sincerely appreciate Mirati’s culture which has provided me that flexibility, and I hope others are increasingly able to work in similar, supportive environments as well.

Effective leadership styles for leaders in STEM fields

Below, Kenna answers questions based on her personal experiences and offers her opinion on effective leadership styles, advice on how to be bold in your career and interesting insight into her important role at Mirati.

Q. Can you describe your role at Mirati?

A. I work in companion diagnostics, and I’m passionate about it because these tests are often overlooked. It is critical that Mirati has access to the technology and devices needed to identify patients so that we can reach patients with the medicines we are creating – this is where I come in. It is important to consider all the decisions that go into the development of one drug treatment; there are just as many decisions required to create a companion diagnostic test.

Q. Tell us more about you. Was there a specific person who influenced you as a person and a leader?

A. I was born into a Midwest family where no one had gone to college, but that didn’t stop my mom from going back to school after her youngest child was in kindergarten. She studied cosmetology and went on to get her license and launch her own successful business. I was about 10 years old when she went back to school while raising three kids. Her commitment to her education was really inspiring to me. It taught me where there’s a will, there’s a way. 

Q. When did you know you wanted to focus on science?

A. I wanted to be in science or medicine from an early age. At one point I considered being a doctor, but while in my double MD/Ph.D. program I quickly realized that was not for me. However, the science part of the program helped me realize my passion is to make sure doctors have everything they need to do their job. I was very drawn to that. From there my passion evolved as I was inspired to advance the cutting edge. Going to the edge is good, but let’s move the edge and drive it forward. This really is the goal of our clinical research.

Q. Do you have any overarching principles that guide your leadership of teams?

A. A good leader is someone who inspires others to do their best work by creating an environment that makes them want to. I have always tried to be a pretty hands-off manager because the most stifling behavior a boss could exhibit is being a micromanager. When I look back on my career, ultimately, I hope my teams know that I was there for them and had their backs.

Q. Were there specific pieces of advice that were consistently given to you as you were growing into leadership roles at the various companies you worked?

A. The consistent thread of advice I have received throughout my career was to not be afraid of the unknown and take chances. I was told “get comfortable with ambiguity”. That is really what science is all about. I worked at a Veterans Affairs hospital while I was in graduate school, and I had a great mentor there who was the head of the lab who would let me rotate through any department I requested within the hospital. I spent two years rotating through different laboratories within the hospital. I look back and that opportunity was such a gift from him, and I would recommend others continually seek and ask for opportunities to learn.

Q. Did you have a mentor? If so, how did that experience help shape you in your career, including as a mentor now yourself?

A. In my time at a previous company, the head of the Oncology Portfolio strongly encouraged me to be the project leader for what turned out to be an incredibly complicated combination program that no one had done before. This mentorship helped push me into this position, which ultimately led to significant professional growth for me. Later, when a mentorship program was rolled out, I took a chance by asking him to be my mentor. I asked because I thought he was the person I could learn the most from, but I fully expected he would say no and refer me to someone else given how demanding his job was. To my surprise he said, “absolutely.” For one year, he never missed a meeting with me. It was terrific. He gave me so much valuable advice that I carried forth to share with my mentees as well. I would have never gotten this benefit if I hadn’t asked. Don’t forget to seek mentors for yourself even as you grow in leadership.

Q. How do you advise other women in STEM navigate a field that can lack diverse representation in leadership roles?

A. It is important not to be afraid of criticism nor be governed by seeking approval. Look for guidance rather than approval. Guidance provides avenues to reach your goals while approval can make you complacent where you are. I also recommend women strengthen their individual voice. Don’t be afraid of the big meetings or feel imposter syndrome when you have earned your spot. Consistently show up and bring a presence when you do.

Q. There are many ways to approach translational medicine. Are there any components to translational medicine that should be more thoroughly addressed today?

A. We should discuss nonresponding patients more. We get incredibly focused on determining how to identify the right patients who may respond, but there are a still many who do not respond. As a translational scientist, I consider what can be learned about those patients who didn’t respond equally important to those who do. It’s important to consider what is different about them. We spend a lot of time collecting data and then asking further questions to uncover more answers. Then, we take that information back to the science lab and consider the other mutational drivers, and how we can advance our approach so that no patient is left behind.

Q. Is the industry shifting their approach to better address this problem?

A. I see an industry trend that is shifting focus to these nonresponders. More people are considering not only how to prolong responses but attempting to understand the rest of the molecular landscape. When we learn not only about the tumor but about that person’s immune system holistically, we can better support that patient to promote longer survival on their current treatment or to begin thinking about what would be next for them. A physician who has a patient on a second line treatment knows the clock is ticking. We do not get very many attempts to treat patients with cancer; there is first line, second line and occasionally third line so it is important to use the best means available based all the information collected.

The power of self advocacy

Below, Lamisa answers questions based on her experience and offers valuable advice about how, and why, it is important to advocate for yourself throughout your career.

Q. When did you learn the power of self-advocacy?

A. I’m a physician by training and before I came to the U.S. for business school, I practiced in India and the U.K. When I started my career and first job in the U.S., I didn’t realize the importance of advocating for myself. I thought I would be considered for the best opportunities simply because my work was so good. But then, I saw myself passed over for new opportunities because I was in the background. This is what changed my perspective. It is important to speak up for yourself. Once I recognized that, I identified my interests, career goals, and how I was positioned for certain opportunities – then I started advocating for myself. This helped me find the right opportunities to advance and best contribute to the company’s success, and my own.

I also noticed throughout my career that people can be subconsciously blind. I used to believe people did not notice skin color, gender, or nationality, but, subconscious bias is real. I believe it is important to remind others what sets you apart.

Q. Is there particular advice that you find yourself giving to other women?

A. Yes. It is not a sprint, it’s a marathon. At times, it can feel as though we are on this milestone-based path and that everything is time bound. Many people can start believing “I need to be manager in two years” or “I need to be VP in four years” and can forget the big picture of what they are trying to accomplish.

When I became a mom, I realized that I am in a completely new category, and I am stretching myself so much. Do I really want to put myself out for a promotion at this time? Can I take more responsibilities or extend my bandwidth and be able to do it justice? If that ‘bigger’ title came two or four years later, does that hurt me? I believe women tend think we need to do “better” all the time. We constantly set what I think are impossible targets or deadlines for ourselves and ultimately harm ourselves trying to reach them.

Q. What are your views on imposter syndrome?

A. It is real. I have felt it several times and I believe women may especially feel the effects of this ‘syndrome’. Some women tend to undersell themselves so when they land in positions they believe they are not qualified for, they feel like an imposter. When considering a job opportunity, I recommend overcoming imposter syndrome by getting into the mindset of the hiring manager who is likely considering whether the potential employee could hit all of the qualifications within a 6–12-month period. This is typically more important than a candidate immediately meeting all of the requirements when hired.

Another facet of advocating for yourself is establishing boundaries at work. Lamisa discussed how she does this to create a successful work/life balance. She also offers her perspective on leadership and why she chose to work at Mirati.

Q. Why are boundaries important at work? Do you set boundaries for yourself?

A. They are critical for ensuring people you work with know what is acceptable and what is not. I believe it is important to establish boundaries upfront or else it can potentially create awkwardness later.

As a working parent of two toddlers, time is precious. I have hard starts and stops. Weekends are off-limits. An understanding boss helps; for me it was easy to align on boundaries and expectations upfront.  Ambition and desire to please everybody can get in the way, so I recommend being deliberate about setting boundaries and adhering to them, setting the example for your team to follow.

Q. What makes a strong leader, in your experience?

A. To me, leadership is about inspiring and motivating a team to deliver their best every day. A strong leader is someone who is humble, a good listener, authentic and compassionate. A strong leader ultimately needs to be able to adapt to meet the needs of the team on any given day.

Q. How do you lift up your team or other colleagues to help them grow their careers?

A. My goal is to understand what that individual wants to do within their career. For example, where do they see themselves in one to two years. Then based on that information I seek to engineer specific experiences, or exposure to specific people, or train them for specific skills that will help them reach their goals. Understanding where employees want to go helps me help them to do so within their current position.

Q. Considering the breadth of this industry, why did you choose to work at Mirati?

A. I chose Mirati because I was fascinated by the science, and I thought it was a very innovative company. I also fell in love with the people that I spoke to as part of my hiring process. I was amazed at what the people I spoke to brought to the table and how much I would get to learn working with them. I was excited about kind of impact that I would be able to have.

I loved that Mirati was thinking about digital innovation. Although we are a small, but growing biotech, we have bold ambitions. Today’s world is increasingly digital. There are infinite technologies that can simplify or automate our business process or allow us to get closer to patient and physicians in a just-in-time manner. These technologies are generating millions of data points, which when analyzed, can inform critical business decisions and allow us to serve our patients and physicians better.

Operating with a growth mindset

The urgency with which we work enables our organization to build from the great work and culture that has been established our humble start nearly ten years ago.

We proudly remain a nimble biotech focused on challenging areas and novel programs – we are not seeking incremental innovation, but on areas that can have a transformative impact for patients.

Our culture is one that values the team over the individual, bold action and an ability to move quickly. We chart our own path.

Truly listening to the people closest to the challenge is an important part of our success.

As we grow and advance our clinical-stage pipeline and approach commercialization, I like to think we prioritize listening and learning over speaking. Finding the right experts both inside and outside the company is essential to filling important gaps and addressing key risks.

I personally spend time with our new team members to talk about the risks of only relying on what you have done before and ensuring that prior experience is not an impediment to relearning new skills or addressing the unique challenges and opportunities we have. Truly listening to the people closest to the challenge is an important part of our success.

Mirati is filled with individuals who have valuable perspectives that will help us to advance our patient-focused goals, but we must first understand what has been done before. Once we understand, we need to operate with a growth mindset, learn from the lessons that came before us, and progress quickly toward the future.

To me, being relentless means we are not anchored in one place. We are constantly learning, improving and moving forward. My team and fellow colleagues “show up” every day, work hard to achieve our shared goals, and constantly put into action innovative ideas to help patients as quickly as possible.

A culture designed to unleash the potential of our people

“We are purposefully building a collaborative team to tackle the problem of understanding and treating cancer head on,” says Jamie Christensen, chief scientific officer, Mirati Therapeutics, Inc. “Bringing together unique skillsets across translational research and discovery science, we are exclusively and aggressively focused on programs where existing interventions are unknown or insufficient.”

Our labs are set up to be integrated so that all disciplines in R&D can benefit from one another and help rapidly share ideas.

From seating charts to lab configurations, we are aspiring to maximize collaboration, curiosity, and our drive to do more for patients.

“We have an open office setting providing an opportunity to intermingle different functions and teams,” says Jamie. “Our labs are set up to be integrated so that all disciplines in R&D can benefit from one another and help rapidly share ideas.”

The Mirati culture is designed to unleash the potential of our science and our people by creating an environment that fosters open-mindedness and collaboration as we seek to transform the lives of patients with cancer. The company’s more than 320 employees are uniformly focused on patients by trying to make a difference with our science and in our communities.

“Where we differentiate ourselves is that we believe in advancing innovative oncology medicines focused on areas with significant unmet needs. Our portfolio is built on what is right in front us – we simply accept the challenge,” says Jamie. “The goal is to do things in a way that will help solve specific problems for identifiable patients by targeting the genetic and immunological drivers of cancer.”

Read more about our science and how we’re tackling cancer head on.

Bridging R&D and the real world

Kelly Covello, head of Medical Affairs, shares a behind-the-scenes glimpse into the dynamic work of the Mirati Medical Affairs team and how their work intersects with patients, patient advocacy groups and healthcare professionals.







I’m in the race of a lifetime

Meeting this mission for patients with cancer means everyone at Mirati, including me, shows up prepared, trained and studied to deliver the best results for those impacted by cancer. When we all do this as individuals and as an organization, we know we left 100 percent on the field. We leave nothing to chance and pursue every opportunity to deliver for patients.

Mirati is in a race to help those with cancer—a race against time for those patients who are waiting for options—and this is the race of a lifetime.

I joined Mirati over a year ago. An important part of my role is to ensure Mirati is ready to be a successful commercial company by assisting in creating capabilities and competencies to commercialize a product effectively and responsibly. I think of my role beyond just those on my team, as we work in partnership across the broader Mirati team to ensure our science is well understood and our compounds, once approved, can deliver the most benefit to those living with cancer.

Mirati’s genesis in discovery and drug development is a core piece of who we are. There is a daring spirit to reach for new horizons, breaking through to discover and advance novel areas of scientific innovation and technology. It’s in our DNA to push the envelope in trying new things to benefit the patients who need us.

Above all, Mirati employees are committed to transforming the lives of those with cancer. We never want to take for granted the opportunity to make a meaningful impact on people’s lives. My team and I view this as our life’s mission and not just as a job. We strive for excellence, seeking those who respect others and find value in others’ differences.

When I first started working in oncology, it was a rational decision, but like many others, it became personal after I lost my father to cancer. That experience taught me that time is not on our side when dealing with this terrible disease.

While time is not on the side of those with cancer, each of us at Mirati are actively and relentlessly on the side of the patient.